– Healthcare institutional investors and insiders commit $15 million through private investment in public equity (“PIPE”)…
Toronto, Ontario–(Newsfile Corp. – March 18, 2022) – ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF)…
Christchurch, New Zealand–(Newsfile Corp. – March 18, 2022) – Today, it has been announced that…
DALLAS–(BUSINESS WIRE)–Drive Shack Inc. (the “Company”) (NYSE: DS), a leading owner and operator of golf-related…
Internet City, Dubai–(Newsfile Corp. – March 17, 2022) – LBank Exchange, a global digital asset…
Dublin, Ireland–(Newsfile Corp. – March 17, 2022) – Ravendex, a fast-growing project built on the…
Netcapital Funding Portal selected among nearly 4,000 nominations across a range of FinTech categories BOSTON–(BUSINESS…
IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM),…
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today…
Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., March 17, 2022 (GLOBE…
Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Cambridge, MA, March…
REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company…
On track to announce initial Phase 1 clinical trial data from two co-lead programs in…
Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data…
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…